Teva Pharmaceuticals USA, Inc Recalls

All product recalls associated with Teva Pharmaceuticals USA, Inc.

Get alerts for this brand

Recall Summary

Total Recalls

14

Past Year

7

Class I (Serious)

0

Most Recent

Nov 2025

Data from FDA, USDA, CPSC, and NHTSA public records. Recall counts vary by company size, industry, and reporting practices. Always check official sources for current information.

Showing 1–14 of 14 recalls

Testosterone Gel 1% (Teva Pharmaceuticals) – leakage risk (2025)

Defective Container - A defect in the side-seal which allows leakage of product.

Class III

FDANov 7, 2025Nationwide• Teva Pharmaceuticals USA, Inc

Amoxicillin Clavulanate Suspension (Teva) – subpotent drug (2025)

Subpotent drug; Clavulanate Potassium component

Class II

FDAOct 13, 2025CA, IN, MS +1 more• Teva Pharmaceuticals USA, Inc

Prazosin Hydrochloride Capsules 2mg (Teva) – Impurity Concerns (2025)

CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.

Class II

FDAOct 7, 2025Nationwide• Teva Pharmaceuticals USA, Inc

Prazosin Hydrochloride Capsules 1mg (Teva) – Impurity Concerns (2025)

CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.

Class II

FDAOct 7, 2025Nationwide• Teva Pharmaceuticals USA, Inc

Prazosin Hydrochloride Capsules 5mg (Teva) – Impurity Concerns (2025)

CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.

Class II

FDAOct 7, 2025Nationwide• Teva Pharmaceuticals USA, Inc

Metoclopramide Tablets (Teva) - Foreign Tablet Contamination (2025)

Presence of foreign tablets/capsules.

Class II

FDAMay 23, 2025Nationwide• Teva Pharmaceuticals USA, Inc

Granix Injection (Teva) – Failed Stability Test (2025)

Failed Stability Specifications - 12-month stability test result for one of the known peptides is below the specification limit

Class II

FDAJan 10, 2025Nationwide• Teva Pharmaceuticals USA, Inc

Testosterone Gel (Teva) – Superpotent Medication (2024)

Superpotent Drug

Class II

FDAAug 8, 2024Nationwide• Teva Pharmaceuticals USA, Inc

Fludrocortisone Acetate Tablets (Teva) – Impurity Concerns (2024)

Failed Impurities/Degradation Specifications: Product is being recalled due to API related substances and unknown impurities that are above the specification limits.

Class II

FDAJun 28, 2024Nationwide• Teva Pharmaceuticals USA, Inc